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Summary: A global human immunodeﬁciency virus-1 (HIV-1) vaccine
will have to elicit immune responses capable of providing protection
against a tremendous diversity of HIV-1 variants. In this review, we
ﬁrst describe the current state of the HIV-1 vaccine ﬁeld, outlining the
immune responses that are desired in a global HIV-1 vaccine. In partic-
ular, we emphasize the likely importance of Env-speciﬁc neutralizing
and non-neutralizing antibodies for protection against HIV-1 acquisi-
tion and the likely importance of effector Gag-speciﬁc T lymphocytes
for virologic control. We then highlight four strategies for developing
a global HIV-1 vaccine. The ﬁrst approach is to design speciﬁc vaccines
for each geographic region that include antigens tailor-made to match
local circulating HIV-1 strains. The second approach is to design a vac-
cine that will elicit Env-speciﬁc antibodies capable of broadly neutraliz-
ing all HIV-1 subtypes. The third approach is to design a vaccine that
will elicit cellular immune responses that are focused on highly con-
served HIV-1 sequences. The fourth approach is to design a vaccine to
elicit highly diverse HIV-1-speciﬁc responses. Finally, we emphasize
the importance of conducting clinical efﬁcacy trials as the only way to
determine which strategies will provide optimal protection against
HIV-1 in humans.
Keywords: HIV, vaccines, viral diversity, immune responses
Introduction
A global human immunodeﬁciency virus-1 (HIV-1) vaccine
will need to elicit durable, potent, and comprehensive
immune responses to provide protection against highly
diverse HIV-1 variants (1, 2). There is more reason than
ever to be hopeful about the development of an effective
global HIV-1 vaccine. The RV144 trial conducted in
Thailand demonstrated that an HIV-1 vaccine was capable of
eliciting modest and transient protection against HIV-1
acquisition (3). A follow-up evaluation of the immune cor-
relates of reduced HIV-1 risk in RV144 has revealed hopeful
leads on how to improve vaccine efﬁcacy, particularly in
terms of the importance of Env-speciﬁc antibodies (4).
Meanwhile, recent advances have allowed the discovery and
characterization of broadly reactive neutralizing antibodies
isolated from HIV-1-infected individuals (5–11). Recent
studies of acute HIV-1 infection have also shown that the
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midable as ﬁrst believed (12), involving single transmitter/
founder viruses that may be easier to neutralize (13).
Given the vast diversity of HIV-1 worldwide, an effective
global HIV-1 vaccine will need to provide protection against
a diverse landscape of HIV-1 sequences in multiple demo-
graphic populations. Moreover, the development of a global
HIV-1 vaccine will require large-scale clinical trials in
human subjects. In this review, we ﬁrst describe the current
state of the HIV-1 vaccine ﬁeld, outlining immune responses
that may be desirable in a global HIV-1 vaccine. We then
discuss select strategies for addressing the challenge of
HIV-1 diversity.
A global vaccine needs a global reach
While there are many challenges in HIV-1 vaccine develop-
ment, a key hurdle is the tremendous genetic diversity of
globally circulating strains of HIV-1 (14–19). Because of the
ability of HIV-1 to evade immune responses through muta-
tional escape, there is constant viral evolution within popu-
lations and individual hosts. The genetic diversity of HIV-1
is attributable in part to the low ﬁdelity of its reverse trans-
criptase, the large number of replication cycles of the virus,
the inﬂuence of innate and adaptive immune responses, and
the ability for HIV-1 to tolerate this diversity (14).
There are thirteen distinct HIV-1 subtypes and sub-sub-
types that are linked geographically or epidemiologically,
with within-subtype variation of envelope proteins of
15–20%, and between-subtype variation of up to 35% (14,
15, 20). Moreover, there are additional circulating recombi-
nant forms (CRFs) generated from genetic mixing in per-
sons dually infected with different subtypes. HIV-1 also
diversiﬁes extensively within each host. For example, Korber
et al. (21) have demonstrated that the variability of HIV-1
within one host is comparable to the global variation of
inﬂuenza A. This genetic diversity makes it difﬁcult to
design an HIV-1 vaccine that will be immunologically
relevant in the face of such a variety of HIV-1 sequences.
Env-speciﬁc antibodies to protect against HIV-1
acquisition
HIV-1 genetic diversity makes it particularly challenging to
design a vaccine that can elicit broadly protective antibodies.
There is an increasing consensus that antibodies speciﬁc to
HIV-1 envelope (Env) will likely be required to block acqui-
sition of HIV-1 (22, 23). Follow-up analyses of RV144
showed that antibodies to variable loops 1 and 2 (V1V2)
regions of HIV-1 Env were associated with a reduced risk of
HIV-1 acquisition (3, 4, 24). A recent genetic analysis
provided further support for the importance of V2-speciﬁc
antibodies by demonstrating that the RV144 vaccine had
increased efﬁcacy against viruses that matched the Env
immunogen in the V2 location (25). Similarly, a recent
study in non-human primates from our group demonstrated
that SIV vaccines using adenovirus and poxvirus vectors
afforded partial protection against neutralization-resistant
SIVmac251 acquisition in rhesus monkeys, and that Env-
speciﬁc antibodies were associated with decreased SIV infec-
tion risk (26). These vaccine-elicited antibodies included
antibodies against V2 as well as other epitopes. Our group
also demonstrated that Env was required to achieve signiﬁ-
cant protection against SIVmac251 challenge, and similar
correlates have been reported by other laboratories against
SIVsmE660 challenges (27, 28).
Neutralizing Env-speciﬁc antibodies have also been shown
to protect against HIV-1 and simian/human immunodeﬁ-
ciency virus (SHIV) acquisition in passive transfer experi-
ments in non-human primates (29–39). For example,
passive transfer of the neutralizing monoclonal antibodies
2F5, 2G12, and 4E10 was shown by Mascola, Hessell, and
others (31–34) to afford partial protection against intrave-
nous and mucosal SHIV challenge. In addition, Hessell, Bur-
ton, and colleagues (35–37) showed that high serum
concentrations of the neutralizing monoclonal antibody b12
protected macaques from intravenous SHIV challenge and
that low concentrations of b12 protected against low-dose
intravaginal SHIV challenge. Monoclonal b12 has also been
shown to protect against SHIV infection when given at
high-doses intravaginally (37, 38). More recently, the
potent neutralizing antibody PGT121 was shown to protect
against high-dose mucosal SHIV challenge in macaques at
serum concentrations signiﬁcantly lower than needed for
protection in prior studies (39).
Non-neutralizing antibodies might also have the potential
to afford partial protection against HIV-1 infection (40, 41).
Non-neutralizing antibodies include various effector func-
tions mediated by the Fc region of the antibody, which trig-
gers the innate immune system to destroy the virus or
virus-infected cells. Follow-up analysis of RV144 showed
that in participants with low serum immunoglobulin A
(IgA) responses, high levels of antibody-dependent cellular
cytotoxicity (ADCC) correlated with a reduced risk of HIV-1
infection (42). In addition, Liao and colleagues (43)
recently demonstrated that V2-speciﬁc antibodies isolated
© 2013 The Authors. Immunological Reviews published by John Wiley & Sons Ltd.
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CD4
+ T cells from RV144 subjects with breakthrough infec-
tions, and that this activity was dependent on V2 position
169 in breakthrough Envs. Theoretically, increased serum
IgA responses might blunt the protective action of non-
neutralizing antibodies because the IgA Fc region does not
mediate the same effector functions, which might explain
why serum IgA levels positively correlated with HIV-1
infection risk in RV144 vaccinees (4). It has also been
shown that broadly neutralizing antibodies also rely on the
Fc region for part of their protective activity (7).
The above studies suggest that Env-speciﬁc antibodies will
likely be necessary to protect against HIV-1 acquisition.
However, these studies do not directly address the challenge
of HIV-1 diversity. For example, the immunogens used in
RV144 matched the local Thai circulating strains of subtype
B and the circulating recombinant form CRF01_AE (3). It is
likely that the Env-speciﬁc antibodies elicited in RV144
would afford a lower degree of protection against other
subtypes of HIV-1 found elsewhere in the world. However,
it remains unclear how a vaccine can elicit antibodies that
will recognize the substantial heterogeneity of Env sequences
globally. Moreover, HIV-1 has other mechanisms to evade
the humoral immune system, including low Env spike den-
sity on the virion surface, heavy glycosylation, conforma-
tional shielding of highly conserved Env epitopes, and
mimicry of Env carbohydrates and proteins of host mole-
cules (9, 10, 44, 45).
Cellular immune responses for virologic control
Given the challenges in eliciting broadly protective Env-
speciﬁc antibodies, it is not likely that any vaccine would
achieve 100% sterilizing immunity in all vaccinees; break-
through HIV-1 infections will likely occur. Thus, it would
be beneﬁcial for an HIV-1 vaccine also to elicit immune
responses capable of controlling viral replication (46). A
wealth of the literature has shown that cellular immune
responses can mediate control of viremia in HIV-1-infected
humans and SIV-infected rhesus monkeys, including CD8
+ T
lymphocytes (47–57), NK cells (58), and CD4
+ T lympho-
cytes (59, 60). Moreover, vaccine trials in non-human pri-
mates have shown that sustained virologic control is
achievable after heterologous SIV challenges. For example,
our group has shown that adenovirus serotype 26 prime
and modiﬁed vaccinia Ankara (MVA) boost expressing SIV
antigens led to a 2.32 log reduction in mean set point viral
load following stringent SIVmac251 challenge, and immune
correlates of virologic control included the magnitude and
breadth of Gag-speciﬁc cellular immune responses (26).
Hansen et al. (56) also demonstrated that early profound
and durable control of SIV replication were achieved in
approximately half of rhesus monkeys immunized with a
rhesus cytomegalovirus vector-based vaccine.
Whereas Env-speciﬁc antibodies appear necessary to block
HIV-1 acquisition, Gag-speciﬁc cellular immune responses
appear important for virologic control. For example, we
have shown that Gag-speciﬁc CD8
+ T cells correlated with
both in vivo and in vitro virologic control following SIV chal-
lenge in vaccinated monkeys; no association was seen with
Env- or Pol-speciﬁc CD8
+ T cells (61). This result is consis-
tent with studies demonstrating the association of Gag-
speciﬁc cellular immune responses with virologic control in
HIV-1-infected individuals (62–68) and SIV-infected rhesus
monkeys (26, 69–71). In addition to Gag, Vif and Nef may
contribute to virologic control in certain settings, such as
Mamu-B*08 monkeys (72).
Another critical aspect of cellular immune responses is the
location and phenotype of cellular immune responses elic-
ited by vaccination. For example, Fukazawa and colleagues
(73) demonstrated that the degree of protection mediated
by a live attenuated SIV vaccine strongly correlated with the
magnitude and function of SIV-speciﬁc, effector T cells in
lymph nodes. They also demonstrated that the maintenance
of these protective T cells was associated with the persistent
replication of vaccine virus in follicular helper T cells.
Despite these observations in non-human primates,
virologic control has yet to be achieved in clinical trials of
HIV-1 vaccines in human subjects. Neither VAX003/004,
the Step study, nor RV144 showed signiﬁcant impact on
viral loads in vaccine recipients who became infected with
HIV-1 (3, 74, 75). However, there was evidence for
immune selection pressure on breakthrough HIV-1
sequences in the Step study, suggesting that vaccine-elicited
cellular immune responses can exert immunologically
relevant biologic effects in humans (76).
Strategies for a global HIV-1 vaccine
The current state of HIV-1 vaccine research suggests that an
effective global HIV-1 vaccine will need to elicit Env-speciﬁc
antibodies to block HIV-1 acquisition and that these
humoral immune responses will need to include either neu-
tralizing or non-neutralizing antibodies (Fig. 1). In addition,
a global HIV-1 vaccine will need to elicit cellular immune
responses to control viral replication for breakthrough
© 2013 The Authors. Immunological Reviews published by John Wiley & Sons Ltd.
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likely need to include Gag-speciﬁc CD8
+ T cells.
It is unclear which HIV-1 antigens to include in a vaccine
to address the challenge of global HIV-1 sequence diversity.
Currently, there are four major strategies toward selecting
antigens for a global HIV-1 vaccine (Table 1). The ﬁrst
approach is to design speciﬁc vaccines for each geographic
region that include antigens tailor-made to match local cir-
culating HIV-1 strains. The goal of these vaccines is to elicit
HIV-1 subtype-speciﬁc immune responses that will have a
higher likelihood of recognizing local strains. The second
approach is to design a vaccine that will elicit Env-speciﬁc
antibodies capable of broadly neutralizing all HIV-1 sub-
types. The third approach is to design a vaccine that will
elicit immune responses that are focused on highly con-
served HIV-1 sequences. The rationale for this strategy is
that these responses will recognize a multitude of different
HIV-1 subtypes via a shared epitope target. The fourth
strategy is to design a vaccine to elicit highly diverse HIV-
1-speciﬁc responses. Here the rationale is that the greater
the breadth and depth of HIV-1 epitopes recognized by
vaccinees, the greater the chance that these immune
responses will match the transmitting HIV-1 strain.
Vaccines to elicit regional HIV-1-speciﬁc immune
responses
One approach to overcoming the challenge of HIV-1 diver-
sity is to design region-speciﬁc vaccines to elicit immune
responses speciﬁc to local circulating HIV-1 strains. Such a
region-speciﬁc vaccine strategy was adopted in RV144,
which used immunogens that matched the local Thai circu-
lating strains of subtype B and the circulating recombinant
form CRF01_AE (3). As discussed above, it would not be
likely that such a region-speciﬁc vaccine would be relevant
in other regions with different subtypes. Such vaccines
would therefore need to be tailored for speciﬁc regions of
the world. For example, as a follow-up to RV144, ALVAC
vectors and gp120 proteins are being produced with sub-
type C immunogens for future clinical trials in South Africa
(12). In theory, similar vaccines could be developed for
subtype B in North America and Europe, subtype A in east
Africa, and so on. A limitation of this approach is that it
would likely be very difﬁcult to test and license multiple
HIV-1 vaccines in different regions of the world. Moreover,
many regions such as central Africa have multiple circulating
subtypes, sub-subtypes, and CRFs in one area.
Even if it proves difﬁcult to develop multiple region-
speciﬁc vaccines, there is substantial interest in improving
the RV144 vaccine for use in Thailand. As noted above, the
ALVAC vector and gp120 protein used in RV144 provided
31% protection against HIV-1 acquisition. While this degree
of protection was modest and transient, there is interest in
improving the RV144 vaccine regimen for possible licensure
in high-risk populations (12). It was noted that vaccine efﬁ-
cacy in RV144 appeared to decline from 60% at 1 year to
31% at 3.5 years, suggesting that increasing the frequency
Fig. 1. Immune responses targeted by a global HIV-1 vaccine.
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cacy. One approach to building on RV144, therefore, is to
use essentially the same vaccine regimen (ALVAC prime/
gp120 boost) but expand the immunization schedule signif-
icantly; clinical trials in Thailand of such an approach are
planned (12).
In addition to changing the RV144 vaccine schedule, there
are also efforts to improve upon the ALVAC vector used in
RV144. Like other poxviruses, ALVAC is well suited to be a
vaccine vector because of its large genome (allowing for the
integration of foreign DNA), thermostability, and the fact that
genome replication occurs in the cytoplasm (77). It was
advanced into Phase III trials in Thailand based on earlier clin-
ical studies that showed that ALVAC vectors expressing sub-
type B Gag and CRF01_AE Env elicited antibody responses
and cellular immune responses (12, 78). Nevertheless, alter-
native poxvirus vectors, such as MVA and NYVAC, are candi-
dates for replacing ALVAC in RV144-like vaccine formulations
(12, 79–84). Future studies using NYVAC vectors and gp120
protein boosts are planned for South Africa.
Vaccines to elicit broadly neutralizing antibodies
A prominent but elusive aim of the ﬁeld is to develop an
HIV-1 vaccine that will elicit antibodies that can neutralize
all circulating HIV-1 sequences (6–10). Neutralizing anti-
bodies do not develop until late in natural infection and in
only 10–30% of HIV-1-infected individuals (9, 85). Until
recently, the ﬁeld was limited by relatively few broadly
neutralizing monoclonal antibodies and a limited number of
epitopic targets (6). However, recent developments in high
throughput single-cell BCR-ampliﬁcation assays have helped
revolutionize the ﬁeld, leading to the isolation and
characterization of dozens of new broadly neutralizing
monoclonal antibodies (11, 86–90). To date, four highly
conserved regions on HIV-1 Env are targeted by broadly
neutralizing antibodies, including the CD4
+ binding site
(CD4bs), a quaternary site on the V1V2 loops, carbohy-
drates on the outer domain, and the membrane-proximal
external region (9). For example, Walker and colleagues
(11) described 17 new PGT antibodies that neutralize
broadly across subtypes, some of which were 10-fold more
potent than the broadly neutralizing antibodies PG9, PG16,
and VRC01. In addition, Scheid and colleagues (87)
identiﬁed a novel class of potent antibodies that mimic CD4
binding entitled ‘highly active agonistic CD4bs antibodies’,
which include broadly neutralizing antibodies NIH45-46
and 3BNC117. Huang and colleagues have also described
10E8, a HIV-1 gp41 membrane-proximal external region-
speciﬁc antibody that neutralized approximately 98 percent
of tested viruses, which was non-self-reactive (90).
Despite the discovery of these remarkable broadly neu-
tralizing monoclonal antibodies, it is still unclear how to
elicit such antibodies by immunization. In fact, a major
gap in the HIV-1 vaccine ﬁeld is the absence of immuno-
gens capable of eliciting neutralizing antibodies of sub-
stantial breadth. Many of the neutralizing monoclonal
antibodies arise from extensive somatic mutation of heavy
chains after years of chronic viral infection. The current
effort to elicit broadly neutralizing antibodies via immuni-
zation uses the structure of previously identiﬁed neutraliz-
ing antibodies as a starting point for immunogen design.
For example, several laboratories have used previously
identiﬁed antibodies, such as the V1V2-directed antibodies
PG9, PG16, and CH01-CH04, to screen for binding to
gp120 envelope monomers which can then be developed
into potential immunogen candidates (10). Other
researchers have centered on designing Env immunogens
to elicit antibodies that resemble the VRC01 antibody,
which binds the highly conserved conformational CD4
binding site (10, 44). Protein scaffolds have also been
used to express neutralizing epitopes (91–93).
Env proteins might be trimers, monomers, or scaffolded
neutralizing antibody epitopes, but all face the same chal-
lenge of achieving extensive somatic mutation seen in the
broadly reactive neutralizing monoclonal antibodies isolated
from chronically infected individuals. One approach to
overcome this challenge is to design vaccines that target
the germline precursors of the desired antibodies, and
that aim to drive appropriate afﬁnity maturation, so-called
‘B-cell-lineage vaccine design’ (45, 86, 94). Another novel
Table 1. Strategies to overcome the challenge of HIV-1 diversity
Vaccines to elicit regional HIV-1-speciﬁc immune responses
Subtype AE immunogens for Southeast Asia
Subtype C immunogens for South Africa
Subtype A immunogens for East Africa
Subtype B immunogens for United States and Europe
Vaccines to elicit broadly neutralizing antibodies
Env monomer immunogens
Env trimer immunogens
Scaffolded neutralizing antibody epitopes
Germline targeted immunogens
Vaccines to elicit highly conserved HIV-1-speciﬁc cellular immune
responses
Conserved epitope immunogens
Conserved region immunogens
Sector immunogens
Vaccines to elicit highly diverse HIV-1-speciﬁc immune responses
Multi-clade immunogens
Mosaic immunogens
© 2013 The Authors. Immunological Reviews published by John Wiley & Sons Ltd.
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broadly neutralizing antibodies directly (95, 96).
Vaccines to elicit highly conserved HIV-1-speciﬁc cellular
immune responses
A third approach to address the challenge of HIV-1 diver-
sity is to design vaccines that will elicit cellular immune
responses speciﬁc to highly conserved HIV-1 regions. The
hypothesis underlying this strategy is that immune
responses speciﬁc for conserved HIV-1 regions will recog-
nize a multitude of different HIV-1 subtypes as the
diverse strains all share a common highly conserved epi-
tope target and that these immune responses will impose
a high ﬁtness cost on any HIV-1 escape viral mutants
(18, 97–99). An initial emphasis was on selecting natural
sequence antigens that may be most conserved among cir-
culating HIV-1 strains. The Step study adopted this
approach, using an adenovirus serotype 5 vector to
express subtype B Gag, Pol, and Nef sequences that were
selected to be phylogenetically close to consensus B
sequences (100, 101). There is evidence that this vaccine
exerted immune selection pressure on breakthrough HIV-1
sequences, but cellular immune breadth was narrow and
insufﬁcient to mediate virologic control (76).
Several other HIV-1 vaccine immunogens have been
designed with the goal of inducing responses against con-
served epitopes, with varying success in preclinical and
clinical studies. For example, the HIVA immunogen, ﬁrst
described in 2000, was derived from the p24 and p17
segments of HIV-1 clade A Gag fused to a string of 25
partially overlapping cytotoxic T-lymphocyte (CTL) epi-
topes (102). HIVA was shown to induce multiple HIV-1-
speciﬁc CTL epitopes when expressed by DNA and MVA
vectors in rhesus monkeys (103) and in a small phase 1
clinical trial in humans (104). However, when the HIVA
immunogen was tried in larger clinical trials, the immuno-
gen induced minimal HIV-1-speciﬁc T lymphocyte
responses (105). Similarly, the EP HIV-1090 immunogen,
ﬁrst described in 2003 as part of a DNA vaccine, was
derived from 21 CTL epitopes of HIV-1 that bound multi-
ple HLA types and represented conserved sequences from
multiple HIV-1 subtypes (106). When tested in humans,
EP HIV-1090 and a later version, EP-1233, were both
poorly immunogenic (80, 107). These studies suggested
that polyepitope immunogens were not optimally pro-
cessed or presented by human immune systems and were
not good candidates for inducing conserved-speciﬁc T lym-
phocyte responses.
Another strategy is to include longer fragments of con-
served HIV-1 regions, as is done in the immunogen
HIVconsv. When expressed by DNA and viral vector vaccines,
HIVconsv has been shown to be immunogenic in preclinical
studies (108, 109). However, we have shown in non-
human primates that at least in certain situations full-length
HIV-1 immunogens elicit increased magnitude and breadth
of cellular immune responses compared with conserved-
region-only HIV-1 immunogens (110). Phase 1 clinical
trials of the safety and immunogenicity of HIVconsv are
ongoing (NCT01151319 and NCT01024842).
A variation of this approach is to design immunogens
based strictly on conserved HIV-1 segments with mutable
regions excluded completely (111). In contrast to the
sequences in HIVA and EP-1033, the conserved sequences
included in these immunogens do not necessarily have to
correspond to any known T-cell epitope. Similarly, Dahirel
and colleagues proposed designing immunogens based on
HIV-1 sequence sectors that exhibit higher order conserva-
tion as measured by random matrix theory (62). These are
sectors in which multiple mutations are very rare, suggest-
ing they are regions of immunologic vulnerability.
Vaccines to elicit highly diverse HIV-1-speciﬁc immune
responses
The above vaccine strategies share a common goal to elicit
immune responses speciﬁc to highly conserved HIV-1
regions, with the hypothesis that these responses will rec-
ognize conserved sequences shared by a wide variety of
HIV-1 strains. A contrasting strategy is to design vaccines
that elicit diverse immune responses speciﬁc for a broad
array of HIV-1-speciﬁc sequences. The hypothesis underly-
ing this strategy is that the greater and more diverse the
immune responses, the greater the likelihood that there will
be a match to the transmitting HIV-1 strain. Diverse
immune responses include T-cell and B-cell speciﬁcities that
recognize multiple HIV-1 regions (breadth) and also multi-
ple variants of HIV-1 epitopes for each epitopic locus
(depth).
Currently, there are two primary approaches for eliciting
broad HIV-1-immune responses via vaccination. The ﬁrst is to
design multivalent immunogens that represent multiple dif-
ferent HIV-1 clades (112). For example, the U.S. Military HIV
Research Program has developed HIV-1 immunogens based
on the predominant HIV-1 subtypes in Kenya, Tanzania,
Uganda, and Thailand (113), and a recent Phase I clinical
study showed that this vaccine was well tolerated and elicited
durable cell-mediated and humoral immune responses (82).
© 2013 The Authors. Immunological Reviews published by John Wiley & Sons Ltd.
300 Immunological Reviews 254/2013
Stephenson & Barouch  A global approach to HIV-1 vaccine developmentSimilarly, a phase II clinical trial sponsored by the HIV Vac-
cines Trial Network (HVTN 505, NCT00865566) tested the
DNA prime/Ad5 boost vaccine expressing Env proteins from
subtypes A, B, and C developed by the NIH Vaccine Research
Center.
The second approach to eliciting broad immune responses
is the design of so-called ‘mosaic’ immunogens (114).
These immunogens are engineered by in silico analysis of
global HIV-1 sequences to provide maximal coverage of
viral sequence diversity (115). Several laboratories have
shown that mosaic HIV-1 immunogens elicited a greater
breadth and depth of HIV-1 cellular immune responses than
consensus or natural HIV-1 immunogens in non-human
primates, as well as comparable or improved Env-speciﬁc
binding and neutralizing antibody responses (116, 117).
Moreover, full-length mosaic HIV-1 immunogens elicited
greater immune responses than conserved-region-only
HIV-1 immunogens (110). Based on these data, mosaic im-
munogens are progressing into clinical development, in the
context of Ad26 and MVA vectors expressing mosaic HIV-1
Gag, Pol, and Env immunogens, as well as in DNA and
NYVAC vectors expressing mosaic HIV-1 Env immunogens.
The vaccines described above are intended to be global
vaccine concepts. Vaccine delivery vehicles will also need to
be globally relevant. One strategy to avoid the problem of
anti-vector immunity is to use plasmids containing HIV-1
DNA sequences, such as VRC-HIVDNA016, a 6-plasmid
multiclade HIV-1 DNA vaccine used in HVTN 505 (118,
119). DNA vaccines can further be improved by electropo-
ration (118). Another strategy to minimize anti-vector
immunity is to use lower seroprevalence or non-human
viruses as vectors (120–125). For example, the lower sero-
prevalence and low titer adenoviruses such as adenovirus
serotype 26 (Ad26) and Ad35 are now being studied as
HIV-1 vaccine vectors (120, 121, 126). Preclinical studies
have shown that these adenoviruses have signiﬁcant biologic
differences from Ad5, the vector used in the Step study that
suggested a possible increased risk of HIV-1 acquisition in
the subset of vaccinees with baseline anti-vector antibodies
(101, 126–133). Ad26 and Ad35 vectors are therefore
planned for further clinical development (134, 135).
Conclusions
The tremendous global diversity of HIV-1 poses one of
the greatest challenges for the development of an effective
global HIV-1 vaccine. Recent research has underscored the
importance of Env-speciﬁc antibodies for blocking HIV-1
acquisition and CD8
+ T lymphocytes for mediating viro-
logic control, yet the optimal strategy for confronting
HIV-1 sequence diversity remains unknown. Here we have
outlined four key strategies for developing a global HIV-1
vaccine, that is, to design vaccines that elicit (i) region-
speciﬁc immune responses; (ii) broadly neutralizing anti-
bodies; (iii) highly conserved cellular immune responses;
or (iv) highly diverse immune responses. The only way
to deﬁne which of these strategies will provide optimal
protection against HIV-1 in humans will be to test a sub-
set of the most promising vaccine strategies in clinical
efﬁcacy trials. By confronting the challenge of HIV-1
sequence diversity, the ﬁeld can move closer to an effec-
tive global HIV-1 vaccine.
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